Business Description
ISIN : US0905722072
Share Class Description:
BIO: Class ATotal Employee Number:
7,450Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.18 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | 2.41 | |||||
Interest Coverage | 4.6 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.64 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.2 | |||||
3-Year EPS without NRI Growth Rate | -11.7 | |||||
3-Year FCF Growth Rate | 72.2 | |||||
3-Year Book Growth Rate | -5.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.09 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.52 | |||||
9-Day RSI | 60.29 | |||||
14-Day RSI | 61.76 | |||||
3-1 Month Momentum % | 24.79 | |||||
6-1 Month Momentum % | 31.82 | |||||
12-1 Month Momentum % | 26.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.14 | |||||
Quick Ratio | 2.33 | |||||
Cash Ratio | 1.68 | |||||
Days Inventory | 227.05 | |||||
Days Sales Outstanding | 63.81 | |||||
Days Payable | 39.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3 | |||||
Shareholder Yield % | 1.37 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.9 | |||||
Operating Margin % | 8.67 | |||||
Net Margin % | 8.59 | |||||
EBITDA Margin % | 21.93 | |||||
FCF Margin % | 13.64 | |||||
OCF Margin % | 19.02 | |||||
ROE % | 3.15 | |||||
ROA % | 2.2 | |||||
ROIC % | 1.73 | |||||
3-Year ROIIC % | 7.53 | |||||
ROC (Joel Greenblatt) % | 24.77 | |||||
ROCE % | 4.24 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 45.66 | |||||
Forward PE Ratio | 36.44 | |||||
PE Ratio without NRI | 58.75 | |||||
Shiller PE Ratio | 16.95 | |||||
Price-to-Owner-Earnings | 26.7 | |||||
PS Ratio | 3.96 | |||||
PB Ratio | 1.4 | |||||
Price-to-Tangible-Book | 1.56 | |||||
Price-to-Free-Cash-Flow | 28.8 | |||||
Price-to-Operating-Cash-Flow | 20.56 | |||||
EV-to-EBIT | 24.57 | |||||
EV-to-Forward-EBIT | 28.58 | |||||
EV-to-EBITDA | 16.16 | |||||
EV-to-Forward-EBITDA | 21.5 | |||||
EV-to-Revenue | 3.79 | |||||
EV-to-Forward-Revenue | 3.8 | |||||
EV-to-FCF | 27.77 | |||||
Price-to-GF-Value | 1.19 | |||||
Price-to-Projected-FCF | 1.14 | |||||
Price-to-Median-PS-Value | 1.02 | |||||
Price-to-Graham-Number | 1.73 | |||||
Earnings Yield (Greenblatt) % | 4.07 | |||||
FCF Yield % | 3.53 | |||||
Forward Rate of Return (Yacktman) % | 22.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:BIO
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Bio-Rad Laboratories Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,589.3 | ||
| EPS (TTM) ($) | 8.254 | ||
| Beta | 1.1674 | ||
| 3-Year Sharpe Ratio | 0.06 | ||
| 3-Year Sortino Ratio | 0.08 | ||
| Volatility % | 30.85 | ||
| 14-Day RSI | 61.76 | ||
| 14-Day ATR ($) | 10.230073 | ||
| 20-Day SMA ($) | 381.381 | ||
| 12-1 Month Momentum % | 26.74 | ||
| 52-Week Range ($) | 236.73 - 396.23 | ||
| Shares Outstanding (Mil) | 26.74 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bio-Rad Laboratories Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bio-Rad Laboratories Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-12 17:00 | In 148 days | ||
| Annual report for 2026 | 2027-02-12 | In 147 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 147 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 17:00 | In 42 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 41 days | ||
| Wells Fargo’s 21st Annual Healthcare Conference | 2026-09-09 15:45 | 380.12 (-2.72%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 17:00 | 334.71 (+2.99%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 334.71 (+2.99%) | ||
| Guidance call for 2026 | 2026-06-03 08:45 | 306.13 (+1.71%) | ||
| Guidance call for 2026 | 2026-05-19 08:30 | 281.82 (+2.58%) |
Bio-Rad Laboratories Inc Frequently Asked Questions
Guru Commentaries on NYSE:BIO
We added to Bio-Rad Laboratories, Inc. (BIO) on weakness during the quarter. This reflects our belief in the company's strong fundamentals and potential for growth, particularly as it operates in a sector that is essential for health care advancements. The market's current pricing may not fully reflect the value and resilience of Bio-Rad's business model, which we see as a significant opportunity for our portfolio.
Bio-Rad Laboratories (BIO) is a global producer of clinical diagnostic and life sciences products, holding a market-leading position in many of its offerings. Approximately 70% of its sales are recurring and consumable, providing a stable revenue stream. Notably, Bio-Rad owns over 35% of Sartorius, a leader in bioprocessing, which significantly contributes to its enterprise value. The current valuation of Bio-Rad appears attractive, especially considering the potential for recovery in fundamentals and the benefits from advancements in AI, which are not yet reflected in market expectations.
We initiated a new position in manufacturer and developer of laboratory equipment and biological testing, Bio-Rad Laboratories Inc. (BIO). The company offers a worldwide presence with the United States representing 42% of revenue, Europe 31%, Asia 21% and Other 6%. BIO offers a solid financial profile, with high and recurring revenue streams as well as rising operating margins. We believe Bio-Rad is a classic Ariel holding, with 80% of sales resulting from products in which Bio-Rad has dominant market share.
Press Release
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
